VISIONS

Koret Vision Institute + Beckman Vision Center + Department of Ophthalmology + Francis I. Proctor Foundation **Summer 2015** University of California, San Francisco + That Man May See

Focal Point

Dear Friends,

In this issue of Visions *we welcome two new faculty members to the Department of Ophthalmology and applaud new leadership for the Proctor Foundation. We introduce pediatric ophthalmologist* ***Anthony T. Moore, FRCOphth,*** *and* ***Majid Moshirfar, MD,*** *an expert in corneal, refractive, and cataract surgery. These world-renowned authorities bring careers of innovation and leadership to UCSF.*

Thomas M. Lietman, MD, *respected for his exceptional international work at the Proctor Foundation, has been appointed its new director and heads a tremendously productive team.*

To save sight for future generations, our vision scientists advance genetics research aimed at cures for blinding diseases. We thank the Claire Giannini Fund for anchor support of this work.

We are pleased to be ranked again among the top six eye institutes nationally for federal research funding. Your gifts to That Man May See's Opportunities Fund for Vision Research help our faculty secure these highly competitive grants.

Thank you for your continued investment in helping our faculty reduce the burden of blindness for so many. We are grateful for your support.

Sincerely,

Stephen D. McLeod, MD
Theresa M. and Wayne M. Caygill, MD, Distinguished Professor and Chair

Dr. Tony Moore and a young retinal patient look to a bright future.

Ophthalmology Insight
The Genetic Frontier

"It's an exciting time," says **Tony Moore, FRCOphth,** a newly arrived British retinal and pediatric specialist at the UCSF Department of Ophthalmology. "Clinical trials of novel treatments such as gene therapy are showing promise for inherited eye diseases that are currently untreatable."

Research breakthroughs are leading toward a new era of personalized treatment, based on each patient's unique genetic makeup (genome). Vision scientists at UC San Francisco are leveraging the latest genetic technologies to advance treatment and research. Their genetic initiatives benefit from collaborations across an unrivaled biomedical research community.

Technological Promise

Genetic mutations are at the root of many diseases, often passed down through families. New genetic sequencing technologies can identify the genetic variants that predispose patients to a particular disease or predict their responses to a treatment. UCSF clinician scientists are already introducing gene-based strategies to diagnose disease, and geneticists in the laboratory work to identify and explore more genes, variants, and mutations that trigger blinding diseases.

Continued on page 2

Director Dr. Thomas Lietman (center) with Associate Director Dr. Nisha Acharya and mentor Dr. Jack Whitcher.

Proctor Foundation
New Director Embraces Powerful Legacy

Thomas Lietman, MD, new director of UCSF's Francis I. Proctor Foundation for Research in Ophthalmology, is dedicated to prevention and treatment of blindness worldwide. The Proctor Foundation has a global reputation for its "gold standard" research on inflammatory and infectious diseases, which very few eye institutes investigate. These diseases take their greatest toll in developing countries, making international initiatives a natural fit.

"Proctor is leading more international clinical trials now than at any time in its history," says uveitis specialist **Nisha Acharya, MD, MS,** "and we hope to continue that trajectory."

Continued on page 2

A PEEK INSIDE:

The Genetic Frontier

Continued from page 1

OCULAR TUMORS – TRANSFORMING CARE

Halting Childhood Blindness

Babies are among the first UCSF ophthalmology patients to benefit from genetic testing. Retinoblastoma is an aggressive, though rare, cancer that can destroy both eyes. It emerges as early as birth and usually by the age of two years.

Dr. Bertil Damato

"Mutations in a single gene are responsible for retinoblastoma," explains ocular oncologist **Bertil Damato, MD, PhD.** "A mutation can be inherited or can occur in the retina."

"Early retinoblastoma treatment greatly reduces the risks of permanent damage and disability," says Dr. Damato, "restoring opportunities for lifetimes of healthy sight." Dr. Damato and his colleagues are developing an online tool to predict new tumors.

Genetic screening for retinoblastoma mutations allows at-risk babies to avoid unnecessary examinations under general anesthesia. The ocular oncology team successfully campaigned for California Children's Services to fund these screenings, allowing more babies the best treatment possible.

To evaluate a novel chemotherapy process for advanced retinoblastoma, the ocular oncology team works with **Katherine Matthay, MD,** and other pediatric oncologists. To enhance holistic care, Dr. Damato is developing a system for measuring retinoblastoma patient/ parent-reported outcomes using online questionnaires.

Screening for retinoblastoma mutations allows at-risk babies to avoid exams under anesthesia.

Partnerships Target Adult Tumors

Uveal melanomas develop in the adult eye. These cancerous tumors can cause blindness and pain, and they become life threatening if they spread to other organs. Most are caused by mutations on a single gene, a fact established by UCSF oncologist **Boris Bastian, MD, PhD.** Dr. Damato's team brings an innovative genetic test, developed by Dr. Bastian, into the eye clinic to learn how many patients with uveal melanomas have a particular mutation that makes their tumor highly lethal. Results to date are very encouraging. To explore the role of long noncoding ribonucleic acids (RNAs) in ocular melanomas, Dr. Damato collaborates with **Susana Ortiz, MD, PhD, MBA.** This research may lead to use of the RNAs as biomarkers, prognostic indicators, predictors of therapy response, and targets for new therapies.

RETINAL DEGENERATIONS – NOVEL TREATMENTS

Taking on the Challenge

Retinal degenerations remain a major challenge in ophthalmology. Most remain untreatable, and eventually lead to severe disability and blindness. Retinal specialists **Jacque Duncan, MD,** and Dr. Moore (pictured on cover) collaborate on caring for retinal patients with vision loss due to retinal degenerations and in research studies to find a cure.

Dr. Jacque Duncan

They also conduct independent research. Dr. Moore is part of a large, international research consortium working to identify more key mutations that predispose people to age-related macular degeneration. Dr. Duncan evaluates novel treatments for a range of inherited retinal diseases.

Genetic Counseling Deepens Care

Dr. Moore is establishing a specialized pediatric retinal disease clinic at UCSF's Visual Center for the Child. He, Dr. Duncan, pediatric ophthalmologist **Alejandra de Alba, MD,** and pediatric medical geneticist **Anne Slavotinek, MD, PhD,** will provide holistic care to young patients and their families. Advanced genetic analysis will allow them to better counsel patients' families, give accurate advice about the likely course of inherited retinal diseases, and allow children to participate in clinical trials of new therapies for their specific retinal disorder.

Rapid Assessment for Clinical Trials

UCSF Ophthalmology is poised to become a major center for clinical trials of new therapies for childhood inherited retinal diseases. Dr. Duncan leads one clinical trial for inherited retinal degenerations, and she is the UCSF principal investigator for two randomized multi-center trials.

The most accurate, high-resolution retinal images possible are produced by the novel imaging system that Dr. Duncan and colleague Austin Roorda, PhD (UC Berkeley) refined. They use it to study patients with inherited retinal degenerations. Because this technology captures the detail of individual light-sensitive cells, it will be invaluable for identifying patients suitable for clinical trials and for more rapid assessment of the effects of novel therapies.

Recent private funding has been provided by Peierls Foundation, Harper-Inglis Memorial Fund for Eye Research, Laurence and Sue Spitters, the Sara and Evan Williams Foundation, and the World Health Organization. Major research support is provided by the Bill & Melinda Gates Foundation and the National Institutes for Health. To learn more about supporting vision research at UCSF, contact Kathleen Rydar at That Man May See, 415.476.4016, rydark@vision.ucsf.edu, or thatmanmaysee.org.

New Director Embraces Powerful Legacy

Continued from page 1

Proctor's committed team of faculty and study coordinators work closely with foreign government health agencies and nongovernmental organizations. Dr. Lietman chose three clinician scientists for greater leadership roles.

Dr. Acharya now serves as associate director; **Jeremy Keenan, MD, MPH,** as director of the International Program; and **John Gonzales, MD,** as director of the Proctor Clinic. "I'm proud to partner with these truly outstanding colleagues to steer the next phase of our work," says Dr. Lietman.

"I'm proud to partner with these truly outstanding colleagues."

– Dr. Thomas Lietman

Changing Lives

The Proctor Foundation was launched in 1947 with the goal of eradicating trachoma worldwide. "The boldness of Proctor's past leaders is an inspiration," says Dr. Lietman. "Jack Whitcher's vision for changing people's lives with big, sight-saving solutions have been instrumental in shaping my thinking."

Jack Whitcher, MD, MPH, led the Proctor Foundation's international efforts until his recent retirement. "Jack's efforts to end corneal blindness in Nepal and India are legendary," recalls Dr. Lietman.

Global and Local Impact

Dr. Lietman is principal investigator for major blindness prevention studies in Africa and Asia. His team's strategies include mathematical modeling to predict rates of infectious disease transmission under a range of conditions. Proctor faculty also conduct research at UCSF. The Proctor Clinic and its laboratory serve patients with corneal and external eye diseases. The foundation works hand in hand with the Department of Ophthalmology to provide patient care and educate the next generation of ophthalmology leaders. ●



Dr. Jeremy Keenan is Director of the International Program.

Dr. John Gonzales is Director of the Proctor Clinic.

DISCOVERIES TO SPARK INNOVATION

Genetic researchers work to identify and understand genes that cause disease. Understanding how different mutations affect cellular function can reveal ways to slow and even prevent disease therapeutically. This approach has successfully identified many genetic mutations that cause major blinding diseases, laying the foundation for innovative, targeted therapies.

Dr. Doug Gould

Retina May Reveal Stroke Risk

Doug Gould, PhD, and his team investigate how mutations of a particular type of collagen (COL4A1) lead to a variety of diseases. Postdoctoral researcher **Marian Jeanne, PhD,** recently published work showing that the same mutations that cause developmental glaucoma (caused by malformations in the front of the eye) also cause abnormal blood vessels in the retina and the brain, leading to hemorrhagic stroke (caused by bleeding in the brain).

Although COL4A1 mutations have only been known for a short while, scientists worldwide have already identified about 100 people with these mutations, and the rate of discovery is increasing. Most of the identified patients have abnormal blood vessels in both brain and retina, and approximately one third also have ocular developmental defects or glaucoma.

One significant implication is that patients at elevated risk for stroke might be identified early if they have abnormal retinal vessels (which can easily be seen during an eye exam). Early detection can lead to early intervention that may ultimately save vision and save lives.

> **"Our collaborative approach advances health worldwide."**
>
> **– Dr. Saidas Nair**

Unraveling Glaucoma's Genetic Mysteries

Saidas Nair, PhD, leads laboratory research that focuses on identifying genetic factors contributing to glaucoma and refractive errors (short-sightedness and far-sightedness). The most common forms of glaucoma and refractive errors are complex diseases, in which disease outcomes are controlled by the interactions of multiple mutations. This inherent complexity makes the identification of disease genes quite challenging. Dr. Nair's lab utilizes experimental model systems that mimic the disease condition to identify likely disease genes.

Dr. Saidas Nair

To uncover the human relevance of the identified candidate genes, Dr. Nair's group interacts with human geneticists. "Enormous pools of patient DNA are needed to find genes and mutations contributing to a complex human disease," explains Dr. Nair. "Geneticists and physicians all over the world understand this need and are joining forces by sharing resources. Our collaborative approach advances health worldwide."

To uncover genetic factors contributing to glaucoma and refractive errors, Dr. Nair's group collaborates with human geneticists at Aravind Hospital in India and Kaiser Permanente Research Division. Their ultimate goal is to determine if some of these factors respond to therapeutic interventions.

> **"Genetics is poised to revolutionize medicine."**
>
> **– Dr. Stephen D. McLeod**

REVOLUTION IN PROGRESS

In the 1990s, the National Institutes of Health boldly launched the Human Genome Project, opening vast new areas of genetic understanding. By 2003, the project had identified most of the genes in the human body and unleashed new genetic research worldwide.

"Today, genetics is poised to revolutionize medicine," says ophthalmology department chair Stephen D. McLeod, MD. UCSF vision scientists stand at the forefront of this personalized medicine frontier. Their genetic discoveries and strategies promise to save sight in California and throughout the world. ●

Major funding for genetics research is provided by the Claire Giannini Fund, the National Institutes of Health. Research to Prevent Blindness, Foundation Fighting Blindness, the U.S. Food and Drug Administration Office of Orphan Product Development, and the Lowy Macular Research Institute. To learn more about supporting vision research at UCSF, contact Kathleen Rydar at That Man May See, 415.476.4016, rydark@vision.ucsf.edu, or thatmanmaysee.org.

That Man May See Celebrates Recent Gifts

Thank you for your generous contributions and pledges for vision research, teaching, patient care, and community outreach received between November 13, 2014, and May 10, 2015. For a complete donor list, please visit www.thatmanmaysee.org/how-you-can-help/contributors/

Distinguished Contributors ($1,000,000+)
Estate of Teresa M. Caygill
Larry L. Hillblom Foundation, Inc.

Benefactors ($500,000+)
Andrew and Cecilia Yau

Honored Patrons ($250,000+)
Hellman Foundation

Visionaries ($100,000+)
Peierls Foundation
Joan and David Traitel

Entrepreneurs ($50,000+)
The Kimball Foundation
Sandler Foundation
The Tumori Foundation
Ronald and Anita Wornick

Investors ($25,000+)
Anonymous
Daniel Benatar
Loretta Emerzian
Carl M. Kawaja
Dr. Thomas and Mrs. Yvonne Mazzocco
Lynn M. Pasternak
Chuck Robel
Jeanne and Sanford Robertson
Venetta and John Rohal
Stephen and Paula Smith
Alejandro A. Zaffaroni, MD, and Leah L. Zaffaroni

Director's Council ($10,000+)
Gerson and Barbara Bakar
Thomas and Johanna Baruch
California Foundation for Molecular Biology
California HealthCare Foundation Oakland, California
BNY Mellon Wealth Management
Devron H. Char, MD
Mrs. Daniel G. Cook
Dr. and Mrs. J. Brooks Crawford
Margaret R. Duflock
Françoise G. Fleishhacker
K. Bruce and Lois Friedman
Dr. and Mrs. Thomas C. Hoyle III
William F. Hoyt, MD
Kawaja Family
James D. and Joan C. Kirsner
Love Family Charitable Fund
Ivan, Maris, and Harry Meyerson
Amy S. Millman and Paul M. Kochis
Norby Anderson
Richard and Candace Olsen
Lisle and Roslyn Payne
Steven L. Pease
JaMel and Tom Perkins Family Foundation Fund
David and Bobbie Pratt
Arthur and Toni Rembe Rock
Schreck Family
Sue and Laurence Spitters
Stephen G. Turner, MD
Ulalani Foundation

Luminaries ($5,000+)
Anonymous
The Bellini Foundation
Buck and Sylvia Breiholz
Geraldine K. Cole
Patrick and Ginger Connolly
Jerome and Catherine Debs
Dr. and Mrs. James E. Dowling
Gloria and Saul Feldman
Dr. and Mrs. Sylvan D. Gross
Matt and Melinda Guelfi
Donald and Roslyn Kahn
Don and Colleen Kieselhorst
Mrs. James P. Livingston
Farideh L. B. Mehran
James and Janet Mitchell
Gerry Marshall and Bernie Newcomb from Bernard A. Newcomb Fund at Silicon Valley Community Foundation
Virginia G. Piper Chairitable Trust
W. Scott Thomas
Ted and Betty Tight
Daniel J. Ullyot, MD
Marilyn and Jack Whitcher
Bruce U. Wintroub, MD, and Marya Wintroub

Dream Makers ($2,500+)
Joan Avenali
Paul and Betty Baldacci Family Foundation
Mr. and Mrs. Paul Bancroft
Edward and Margaret Collins
Mr. and Mrs. Donald W. Davis
John F. de Benedetti and Nina K. Srejovic
Dr. and Mrs. Eugene de Juan Jr.
Shustek Dubinsky Family Philanthropic Fund
The Enersen Foundation
Tom and Gunilla Follett
Mary Ellen and Michael E. Fox Family Foundation
Bernard and Leah Freiwald
Paul and Béatrice Gomory
Lorie and Ron Hirson
Alfred Hom
Drs. Alex and Chauncy Irvine
Lydia A. Lukian, MD
Donna L. and Edward E. Martins Foundation Inc.

Continued on page 7

New Faculty

Anthony T. Moore, FRCOphth

Pediatric Ophthalmologist and Inherited Eye Disease Specialist

School of Medicine: Oxford University

Fellowships: Pediatric Ophthalmology, Hospital for Sick Children, Toronto; Medical Retina, Moorfields Eye Hospital, London

Previous Positions: Duke-Elder Professor of Ophthalmology, UCL Institute of Ophthalmology and Moorfields Eye Hospital, London; Director of the Inherited Eye Disease Service, Moorfields Eye Hospital

Q You lived in London for many years. What's it like to move to San Francisco?

A The fact that everyone at UCSF has been so welcoming has been a great help. In the UK, I lived and worked in London during the week and spent weekends in Cambridge. San Francisco falls somewhere between the two. Its multi-ethnic feel is similar to London's, but it's less hectic. San Francisco is very walkable, and I am getting much fitter!

Q Your collaborations with geneticists have yielded important findings. Can you share a breakthrough?

A Sure. Our research group in Cambridge was the first to identify a key gene (C3) predisposing individuals to age-related macular generation (AMD). The work also highlighted smoking as a very strong risk factor. The C3 gene is now used to screen patients for AMD.

Q Tell us about a research project for pediatric patients.

A My London research focused on finding genes causing childhood inherited retinal disease and working with Professor Robin Ali, a gene therapy expert. I was involved in a clinical trial for infants with Leber congenital amaurosis that was the first to demonstrate that gene therapy can improve retinal function in inherited retinal disease.

Q How does British medicine utilize genetics?

A Under socialized medicine, it is easier to establish a national strategy for rare inherited diseases and genetic testing. It also can help drive research. For example, the National Health Service is funding whole genome sequencing of 100,000 patients with genetic disorders. In the United States, insurance companies have yet to realize that genetic diagnosis will save them money. Costs are shrinking, and I expect testing to become universally available in the near future.

Q You've received major recognition for your contributions to ophthalmology. What award means the most to you?

A The 2011 Doyne Lecture and Doyne Medal of the Oxford Congress are the highlights. The prestigious list of awardees includes many international leaders. It means even more because I went to medical school at Oxford and worked as a junior resident at the Oxford Eye Hospital, where the visionary Robert Doyne himself was once on staff.

Q What do you hope to accomplish at UCSF?

A First of all, this outstanding department provides a strong base. I would like to build on this and strengthen links between UCSF's excellent and diverse basic science disciplines and ophthalmology. My goal is to develop new treatments for childhood blinding disorders.

Q What is your favorite lunch spot near the Parnassus campus?

A Martha & Brothers coffee shop on Irving Street has great coffee, and I recommend their BLT bagel!

Donor Impact

Planting Seeds for Scientific Discovery

Donations of every size to That Man May See are leveraged to support discoveries aimed at saving and restoring sight. When philanthropists seed fund novel research, vision scientists can develop evidence to garner major support from the National Institutes of Health (NIH). UC San Francisco Ophthalmology has attracted more than $9.5 million in current federal research funding.

This record of success places UCSF Ophthalmology among the top six universities nationwide for NIH vision research funding. This is especially noteworthy given UCSF's smaller vision research faculty and facilities, in comparison with other leading eye institutes. The ranking reflects research expertise – a powerful indicator that patients receive the very best ophthalmic care.

"Our vision researchers are making tremendous progress," says Department Chair **Stephen D. McLeod, MD.** "The challenge, as we are all aware, is that federal research funds are increasingly constrained."

UCSF Opht places the top six nation

Fertile Ground for New Findings

Charitable seed funding helps to keep the laboratory of **Douglas Gould, PhD,** on the forefront of human genetics. Dr. Gould and his colleagues use their knowledge and expertise in genes and gene mutations to study a variety of conditions and how alterations at the cellular level contribute to vision disorders. Dr. Gould leveraged early, privately funded research to make the case for federal support. Now NIH funds will allow his team to study the role of collagen and matrix proteins in glaucoma and age-related macular degeneration.

Understanding the basis for visual perception in the brain is the principal focus of **Jonathan C. Horton, MD, PhD,** and his Laboratory for Visual Neuroscience. His team is concerned with deviation in the alignment of the eyes, a common disorder called strabismus. Dr. Horton notes that "development of better treatments has been

Majid Moshirfar, MD

Cornea, Cataract, and Refractive Surgery Specialist

School of Medicine: Georgetown University

Fellowships: University of Utah – Cornea/External Disease, Refractive Vision Correction Surgeries, and Anterior Segment Reconstruction

Previous Position: Director, Refractive Surgery and Cornea Programs, Moran Eye Center, University of Utah



Q Please tell us where you grew up and how vision science became your calling.

A I grew up in Iran until I was seventeen and finished high school in Geneva, Switzerland, before I moved to the States. I witnessed cataract surgery on a few of my family members when I was a very young boy, and I was fascinated with optical equipment. My interest in the Hubble Space Telescope and physics also had an impact.

Q You are known for pioneering cataract and refractive surgery technologies. How does a surgeon innovate, and what approaches are you excited about right now?

A Surgical innovation involves working hand in hand with device makers to realize a novel surgical approach or solution. For patients with "end-stage" age-related macular degeneration, I have begun implanting a miniature telescope into the front of the eye (see image and description below). It's a fascinating approach that is allowing elderly people to recover some sight.

New materials and techniques in artificial cornea implantation are improving outcomes for patients with severe corneal damage. Also, phakic intraocular lenses can help patients with extremely severe myopia. I was involved in testing early models of the lens prior to U.S. approval.

Q You've published more than 170 scientific articles. What is the impact of your research on current surgical practices?

A Thousands of surgeons perform corneal and LASIK surgeries, but just a handful have the opportunity to analyze the procedures and outcomes. The results of my study on the incidence of keratectasia after LASIK surgery were downloaded more than 7,000 times. This shows that surgeons need this kind of information to make wiser choices for their patients.

Q Beyond clinical practice and teaching, you research, publish, and serve on nine editorial boards. How do you find balance?

A I enjoy the Persian literature of Rumi and spend most of my free time with my family. I enjoy Pilates and yoga. My passion is active involvement in charity medical care for underserved communities both nationally and internationally.

hampered by limited understanding of the sensory and motor adaptations that occur in this disease." A new federal award allows Dr. Horton and his team to continue research to prevent and treat strabismus.

Jeremy Keenan, MD, MPH, investigates how to eliminate trachoma in international communities. Trachoma is a highly infectious eye disease that causes blindness. Globally, approximately 40 million people have trachoma, and clinically active trachoma may be present in as many as 60–90 percent of children in some areas. Dr. Keenan used seed funds to explore whether improved access to clean water and sanitation is part of a cost-effective strategy to eliminate trachoma. Promising results led to an NIH award, and he has expanded the project to 68 rural Ethiopian communities.

thalmology among universities nwide.

Harvesting Hope

Today's vision research ideas are the root of tomorrow's sight-saving breakthroughs. Please join us on this journey of discovery by making a charitable donation today to That Man May See. Your seed funds can grow for powerful outcomes, bringing hope to patients today and for generations to come. ●

Seed funding was provided by donors to That Man May See. Special thanks to the Larry L. Hillblom Foundation and the Sara and Evan Williams Foundation. To learn more about supporting vision research at UCSF, contact Robin Morjikian at 415.476.2950, morjikianr@vision.ucsf.edu, or thatmanmaysee.org.



Implantable Telescope for AMD

A novel implantable telescope can restore some sight to patients with end-stage age-related macular degeneration. Approved in the United States in 2014, the device incorporates wide-angle micro-optical lenses. In concert with the cornea, the technology enlarges images in front of the eye to more than twice their normal size. The magnification allows central images to be projected onto healthy photoreceptors.

Faculty News

Dr. Jennifer Rose-Nussbaumer
Comparing Sight-Restoring Transplants

Cornea specialist **Jennifer Rose-Nussbaumer, MD,** wants vision patients around the world to share the opportunity her UCSF patients have – to reverse blindness with a corneal transplant. She hopes to expand these surgeries to more countries, and her research raises the level of scrutiny given to transplant techniques.

Dr. Rose-Nussbaumer and collaborator Winston Chamberlain, MD, PhD, of the Casey Eye Institute, are conducting a clinical trial to analyze

Surgical research raises the level of scrutiny given to transplant techniques.

outcomes of approximately 50 patients randomized to receive one of two partial-thickness corneal transplants: the ultrathin descemet's stripping automated endothelial keratoplasty or a more recently developed procedure, the descemet membrane endothelial keratoplasty.

As part of the UCSF Proctor Foundation's international team, Dr. Rose-Nussbaumer aims to expand on these corneal transplant studies in Nepal. "Corneal blindness is concentrated in countries where manual field labor still predominates," she says.

Her future studies will evaluate which techniques can be best adapted to resource-poor settings. They could also answer some important questions for the field of cornea. ●

Richard L. Abbott, MD
Keynote Speaker: "Off-label drug use in the USA: The current status for ophthalmologists," Italian Society of Ophthalmology, national meeting, Rome

Appointment: Visiting Professor in Residence, University of Bologna, Department of Ophthalmology

David R. Copenhagen, PhD
Invited Lecturer: "Influence of intrinsically photosensitive retinal ganglion cells on neural and vascular development of the eye," Joint American Academy of Optometry/Association for Research in Vision and Ophthalmology, Symposium, Annual Meeting, Denver

Jacque L. Duncan, MD
Appointment: Chair of the scientific advisory board, Foundation Fighting Blindness

Felice Dunn, PhD
Invited Lecturer: "Signal and noise properties of different bipolar cell types in the mouse retina," Joint American Academy of Optometry/Association for Research in Vision and Ophthalmology, Symposium, Annual Meeting, Denver

Shan Lin, MD
Appointment: Chair of the American Glaucoma Society Symposium, Asia-Pacific Academy of Ophthalmology, Guangzhou, China

Saidas Nair, PhD
Invited Lecturer: "Complex genetics of glaucoma: what animal models can teach us," Bay Area Vision Research Day, University of California, Berkeley

Erik M. Ullian, PhD
Publication: Krencik R, Hokanson KC, Narayan AR, Dvornik J, Rooney GE, Rauen KA, Weiss LA, Rowitch DH, **Ullian EM**. Dysregulation of astrocyte extracellular signaling in Costello syndrome, *Science Translational Medicine*, 2015 May 6;7(286):286ra66. doi: 10.1126/scitranslmed.aaa5645

A Perspectives article on the impact of the Ullian team's paper was published the same week. Xing L, Li X, Snider WD. "RASopathic" astrocytes constrain neural plasticity, *Science*, 2015 May 8:Vol. 348 no. 6235, pp. 636-637doi: 10.1126/science.aab3738

Proctor Foundation

Publication: **Rose-Nussbaumer J, Prajna, NV, Krishnan KT, Mascarenhas J, Rajaraman R, Srinivasan M, Raghavan A, Oldenburg CE, O'Brien KS, Ray KJ, McLeod SD, Porco TC, Lietman TM, Acharya NR, Keenan JD**. "Vision-related quality-of-life outcomes in the mycotic ulcer treatment trial 1, a randomized clinical trial," *Journal of the American Medical Association Ophthalmology*, published online 2015, Mar 12. doi:10.1001/jamaophthalmol.2015.0319

The researchers found evidence of improvement in vision-related quality of life among patients with fungal ulcers randomly assigned to natamycin compared with those randomly assigned to voriconazole, especially among patients with *Fusarium* species as the causative organism.

Koret Vision Research Laboratories + Beckman Vision Center + Proctor Foundation

Facilities of UCSF Ophthalmology

University of California
San Francisco
Department of Ophthalmology
10 Koret Way, Room K-301
San Francisco, CA 94143-0730
www.ucsfeye.net

Francis I. Proctor Foundation
95 Kirkham Street
San Francisco, CA 94143-0944
proctor.ucsf.edu

HOW TO REACH US

Comprehensive Eye Center
415.353.2800
Routine eye care, acute care, eye disease referrals

Eyeglasses & Contact Lenses
415.476.3100

Cataract and Cornea Care
415.514.8200

Glaucoma Care
415.514.6920

Neuro-Ophthalmology
415.476.7176

Ocular Oncology Care
415.514.8722

Ocular Plastic Surgery
415.353.2800

Pediatric Ophthalmology
415.514.3916

Proctor Medical Group
415.476.1442

Retinal Care
415.353.2800

Vision Correction Surgery Center
415.353.2020
Individualized vision correction surgery, including LASIK and PRK

In Memoriam

Supporting Breakthroughs for Macular Degeneration

A dear friend of That Man May See, **Geraldine Kennedy Cole**, supported vision research so that future generations would be spared from loss of sight. Gerry passed away on January 14 in Carmel Valley. An avid reader and collector of rare books, Gerry and her late husband Jerry loyally made generous contributions to That Man May See over four decades.

The couple's relationship with the foundation was encouraged by Gerry's childhood friend **Stacy R. Mettier Jr., MD,** a founder of That Man May See. He introduced the Coles to the UCSF vision scientists.

A native of San Francisco, Gerry was a direct descendant of early California pioneer families. Gerry's love of nature and fine printing led her to the works of Thomas Bewick, an English engraver and naturalist of the late 18th and early 19th centuries. She and Jerry traveled extensively, exploring bookshops, libraries, and museums to learn about and collect the engraver's works.

Gerry also had a lifetime love of reading and needlework, and in later years she enjoyed paper marbling. Her loss of vision to macular degeneration in the last years of her life was a struggle and a challenge. She often told her children that someday That Man May See would fund a project that would at last end macular degeneration. That gave her hope with each donation.

Acknowledging the devastation of macular degeneration, Gerry's family invites contributions in her memory to That Man May See at www.thatmanmaysee.org, 10 Koret Way, Box 0352, San Francisco, CA 94143-0352, or 415.476.4016. ●

Recent Gifts to That Man May See

Continued from page 3

Stephen D. McLeod, MD, and Marion Faymonville
Dr. and Mrs. Stacy R. Mettier Jr.
Joan Platt
Judy and Fred Riedel
Bob and Naomi Stamper
John and Peggy Stock
Camele S. Wanat
Ira G. Wong, MD, MS, and Eleanor W. Wong

Innovators ($1,000+)
Anonymous (4)
Richard L. and Cecilia Abbott
Timothy G. Berger, MD, and Jessica O'Dwyer
Becky and Jeff Bleich
Roger and Nancy Boas
H. Michael Braude
Dr. and Mrs. William S. Breall
John and Leeana Brichetto
David F. Chang, MD, and Victoria A. Chang
Chevron Humankind Program
Bruce and Suzanne Crocker
Mr. Gary A. D'Acquisto
Elayne R. Dauber and Philip S. Dauber
Rosalind Gray Davis and Robert M. Davis
Hal Dawson and Mary McVey
Paula Dawson
Mariann Di Minno
Sue and John Diekman
John and Marilyn Dougery
Dr. and Mrs. James F. Eggert
Allan J. Flach, MD, PharmD, and Teri Flach
Suzanne Gorte
Lorrie and Richard Greene
Robert A. Grimm
Larry and Carie Haimovitch
Rod and Carole Hartless
James R. Hollander
Jonathan C. Horton, MD, PhD
Huntington Farms
Arlene Inch
David K. Ingalls
Margaret M. Jacobsen
Ottiwell W. Jones III, MD
Louise and Howard Karr Fund at Silicon Valley Community Foundation
Nick and Becky Kemsley
Donald R. and Judith D. Krohn
Dr. and Mrs. Shiu Y. Kwok
Stephanie LeGras
Mary Lou Lewis, MD
Bill and Barbara Loveless
Dave H. and Diane M. Luders
Zoya A. Lukian
Angus L. and Virginia MacLean Jr.
The Mattson Family Conservation Foundation
Joan and Roger McGee
Tara K. Mochizuki and Jeffrey M. Chu
Anthony and Lary Lynn Muller Fund of the Community Foundation for Monterey County
Robert E. Nasser, MD, and Carol Nasser
Wendell and Germaine Norwood
Owen and E. Toki Oakley
Rosanne and Michael Ogles
Barry Petersen
Ed and Marcia Pollack
Frank and Denise Quattrone Foundation
Virginia M. Ratto
Barbara H. Rosston at Silicon Valley Community Foundation
John C. and Diane W. Savage
Robert and Isabel Schuchardt
Michael and Susan Schwartz Fund at Marin Community Foundation
Edward C. Shotwell III 1996 Charitable Annuity Lead Trust
L. Aline Sinai
James Hart and Mary Pfeiffer Smith
R. G. Starmann Sr.
Judith Good Stearns
R. B. and Jean C. Switzer
Ann and Marshall Turner
R. Douglas Wayman, MD, and Shirley Wayman
Morey Weingarten, MD
U. Christina West, MD, and William B. Conerly
Diane Wilsey
Burton L. Wise, MD, and Myra Wise, PhD
Eric Zankman and Pamela Kaufmann
Peggy and Lee Zeigler
Andy Zwick

To Make a Bequest

A Dream to Benefit Vision

In 1944, **Ruth Hoffman** left Chicago on a bicycle, heading for California. She had a dream to live in San Francisco.

Raised with a high regard for education, Ruth earned a degree in psychology at the University of Chicago before following her sense of adventure. At the Nevada/California border, she found Kaiser recruiters seeking workers for the shipyard. The Bancroft Library's "Rosie the Riveter" project includes an interview with Ruth, preserving her philosophy, travels, and career. After a short shipyard stint, Ruth became a teacher and eventually a probation officer for the Contra Costa County Juvenile Court.

Ruth and her husband Bill are including That Man May See and vision research in their estate plan. "We have to give of ourselves," Ruth says.

Leaving a bequest like this can offer sight to future generations. Their gift honors Eugene Dillon and Drs. O'Neill and Marcia Dillon. The two Dillon brothers, Eugene and O'Neill, met Ruth when they were just four and five years of age, and Ruth became their mentor. Through a reunion after the Hoffmans married, these families became lifelong friends. ●

To leave a legacy through a planned gift, contact Kathleen Rydar at That Man May See at 415.476.4016 or rydark@vision.ucsf.edu or www.thatmanmaysee.org.

That Man May See is a 501(c)3 public charity. Its mission is to raise funds for the dedicated faculty of UCSF Ophthalmology to make possible breakthroughs in vision research, state-of-the-art patient care, educational opportunities for residents and fellows, and community service.

To make a gift of cash or securities, go to www.thatmanmaysee.org/donate or call 415.476.4016 or email tmms@vision.ucsf.edu. Checks are payable to That Man May See.

That Man May See
10 Koret Way, Box 0352
San Francisco, CA 94143-0352
tmms@vision.ucsf.edu
VISIONS is a publication of the Department of Ophthalmology at UCSF and is produced by That Man May See.

For a free subscription to VISIONS magazine, please call 415.476.4016 or go to www.thatmanmaysee,org/why-it-matters/visions-magazine

To receive or cancel further fundraising communications from the Department of Ophthalmology or That Man May See, please contact:
Records Manager
Department of Ophthalmology, UCSF
Box 0248
San Francisco, CA 94143-0248

VISIONS
UCSF University of California San Francisco, CA 94143
THAT MAN MAY SEE 415.476.4016
RETURN SERVICE REQUESTED
NON-PROFIT ORG. U.S. POSTAGE PAID SAN FRANCISCO, CA Permit No. 8285

Help save sight and save lives.

Visit us on the web at www.thatmanmaysee.org

Genetic Frontier for Vision

Proctor Leadership

Make Waves with Us!

Register now to swim in our **4th Annual Alcatraz Swim for Sight**, Sunday, November 1, 2015. To sign up, sponsor a swimmer, or make a donation, visit www.thatmanmaysee.org/alcatraz or contact Robin Morjikian at morjikianr@vision.ucsf.edu or 415.476.2950.

Mission Bay Campus

New Site for Young Eyes

The Department of Ophthalmology's **Visual Center for the Child** is now located in the UCSF Ron Conway Family Gateway Medical Building at Mission Bay. Part of the UCSF Medical Center, the building houses an array of outpatient services for children and is adjacent to the new UCSF Benioff Children's Hospital San Francisco. The inviting space welcomes children and families with expanded clinical facilities and innovative play areas. The Visual Center for the Child gives families access to a wide range of specialists, making it a "one-stop shop" for most pediatric eye patients who require team care.

1825 Fourth Street, Fifth floor. For a map and directions, go to www.ucsfhealth.org/maps_and_directions/mission_bay/index.html ●

Capital and endowment support to establish the Visual Center for the Child was provided by an anonymous distinguished contributor, visionary funders L. Aline Sinai and The David and Elva Sinai Foundation, Inc., William Randolph Hearst Foundation, and other generous friends.